statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Designed to provide broad exposure to the Small Cap Blend segment of the US equity market, the iShares Morningstar Small-Cap ETF (ISCB) is a passively managed exchange traded fund launched on...

Should iShares Morningstar Small-Cap ETF (ISCB) Be on Your Investing Radar?

The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure...

2 Biotech Stocks to Buy Hand Over Fist in April

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) and PTC Therapeutics (NASDAQ:PTCT - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two...

Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & PTC Therapeutics (NASDAQ:PTCT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously approved by the Compensation...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have added about 1.2% in that time frame, underperforming the S&P 500.Will the recent positive trend...

Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?

This is a Bullish indicator signaling SRPT's price could rise from here. Traders may explore going long the stock or buying call options...

Sarepta Therapeutics (SRPT, $127.94) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 25, 2024

Oppenheimer analyst Hartaj Singh maintained a Hold rating on Sarepta Therapeutics (SRPT Research Report) today. The company's shares closed yeste...

Oppenheimer Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

Handelsinvest Investeringsforvaltning bought a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT  Free Report) during the fourth quarter, according to the company in its most...

Handelsinvest Investeringsforvaltning Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Vanguard Group Inc. raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT  Free Report) by 0.5% during the third quarter, according to its most recent 13F filing with the...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Vanguard Group Inc.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT  Free Report)  Equities research analysts at Zacks Research decreased their Q1 2025 earnings estimates for shares of Sarepta Therapeutics in a...

Q1 2025 EPS Estimates for Sarepta Therapeutics, Inc. Cut by Zacks Research (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Volume	1.24M
52-Wk High	$159.89
52-Wk Low	$55.25

SRPT Sarepta Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals